OmniAb reports Q2 2025 revenue $3.9M, net loss $15.9M; affirms $20-25M FY revenue guidance

OmniAb, Inc.

2025-Q2 EPS reported -$0.32 revenue$8,051,000

Q2 revenue $3.9M (down 49% YoY) on lower milestone and service revenue; net loss $15.9M ($0.15/sh) vs $13.6M ($0.13) in Q2 2024.
2025 guidance: revenue $20M-$25M, operating costs $85M-$90M, cash use expected below 2024's $38.9M (ex-ATM).
100 active partners and 381 active programs as of June 30, 2025, including 32 OmniAb-derived programs in clinical development.
Sold small-molecule Kv7.2 program to Angelini Pharma for $3M upfront; eligible for >$170M milestones plus royalties.
Launched xPloration Partner Access Program for high-throughput B-cell screening; xPloration won 2025 Best of Show at PEGS Boston.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.